KBC Group NV reduced its stake in Bank of America (NYSE:BAC) by 0.9% during the fourth quarter, selling 81,789 shares, but still holds over 9.1 million shares valued at approximately $502.8 million. Other institutional investors also adjusted their positions in BAC. The article also provides recent analyst ratings, financial performance, dividend information, and details on insider activity for Bank of America.

KBC Group NV increased its stake in Boston Scientific Corporation (NYSE:BSX) by 2.9% during the fourth quarter, now owning 3,044,385 shares valued at $290.28 million. Other institutional investors also adjusted their holdings, and 89.07% of the stock is currently owned by institutional investors. Recent news for Boston Scientific includes continued analyst support, positive earnings expectations, an update on the competitive landscape, and rising legal risk due to recent class-action lawsuit filings.

KBC Group NV increased its stake in Citigroup Inc. (NYSE:C) by 3.4% in the fourth quarter, now owning 3,839,880 shares valued at $448.075 million. The article also highlights recent positive analyst ratings and forecasts for Citigroup, along with a strong Q1 earnings report that beat expectations. However, it also notes negative sentiments regarding the company's private-credit exposure and increased regulatory scrutiny in that market.

KBC Group NV increased its stake in Pfizer Inc. by 8.3% during the fourth quarter, purchasing 706,426 additional shares to bring its total holding to 9,193,713 shares, valued at approximately $228.9 million. This makes KBC Group NV own about 0.16% of Pfizer, with institutional investors collectively owning 68.36% of the company. Despite Pfizer beating Q4 earnings estimates with an EPS of $0.66 and revenue of $17.56 billion, analysts maintain a consensus "Hold" rating with a target price of $28.24.

KBC Group NV increased its stake in Cardinal Health, Inc. (NYSE:CAH) by 0.6% in the fourth quarter, bringing its total ownership to 1,021,940 shares valued at $210,008,000. Cardinal Health recently surpassed earnings expectations with EPS of $2.63 and revenue of $65.63 billion, leading analysts to issue a "Moderate Buy" consensus rating and an average price target of $244.33. The company also declared a quarterly dividend of $0.5107 per share.

Lbp Am Sa significantly increased its stake in Pfizer Inc. (NYSE:PFE) by 190.9% in the fourth quarter, bringing its total holdings to over 1 million shares valued at $25.32 million. Other institutional investors like Franklin Resources, Neuberger Berman Group, Ameriprise Financial, AQR Capital Management, and Amundi also increased their positions in the biopharmaceutical company during the third quarter. Pfizer's stock currently has an average "Hold" rating from analysts with a consensus target price of $28.24, following its recent earnings beat and analyst target adjustments.

KBC Group NV reduced its stake in The Progressive Corporation by 32.5% in Q4, selling over 200,000 shares and now owning 0.07% of the company. Progressive (NYSE:PGR) exceeded Q1 EPS expectations, reporting strong underwriting results and a 6.5% year-over-year revenue increase. Despite mixed insider and institutional trading activity, analysts generally maintain a "Hold" rating with an average price target of $237.50.

KBC Group NV increased its stake in CF Industries Holdings, Inc. by 26.9% in Q4, bringing its total to 1,170,171 shares worth approximately $90.5 million. Despite significant institutional accumulation, corporate insiders have sold 82,408 shares valued at about $9.97 million in the last quarter. CF Industries exceeded Q4 earnings estimates with $2.59 EPS and $1.87 billion in revenue and maintains a "Hold" rating from analysts with an average target price of $114.20.

Lbp Am Sa reduced its stake in Church & Dwight Co., Inc. (NYSE:CHD) by 11.1% in the fourth quarter, selling 32,359 shares and holding 259,370 shares valued at $21,748,000. Several other institutional investors also adjusted their positions in the company. Church & Dwight recently reported strong earnings, topping analyst estimates, and increased its quarterly dividend to $0.3075 per share.

Lbp Am Sa increased its holdings in Colgate-Palmolive Company (NYSE:CL) by 14.8% in the fourth quarter, now owning 262,102 shares valued at $20.71 million. Several other institutional investors also adjusted their positions in CL. Analysts have set a consensus target price of $95.56, with a "Moderate Buy" rating for the stock.